Sign In
Buy OTIC
$0.0085
+0 (+0%)
At Close: Jul 11, 2023
Will Otonomy (OTIC) Report Negative Q2 Earnings? What You Should Know
04:05pm, Tuesday, 27'th Jul 2021
Otonomy (OTIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Otonomy Initiates Expansion of Phase 1/2 Clinical Trial for OTO-413 in Hearing Loss
07:30am, Tuesday, 15'th Jun 2021
SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the ini
Otonomy and AGTC Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting
07:30am, Friday, 14'th May 2021
OTO-825 administration rescues hearing and cochlear damage in two preclinical models of congenital hearing loss caused by GJB2 deficiency OTO-825 administration rescues hearing and cochlear damage in
Otonomy, Inc. (OTIC) CEO David Weber on Q1 2021 Results - Earnings Call Transcript
09:17pm, Tuesday, 11'th May 2021
Otonomy, Inc. (OTIC) CEO David Weber on Q1 2021 Results - Earnings Call Transcript
Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update
04:17pm, Tuesday, 11'th May 2021
Conference call and webcast today at 4:30 p.m. ET
Otonomy to Report First Quarter 2021 Financial Results and Provide Corporate Update
07:30am, Tuesday, 04'th May 2021
SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will
Otonomy and AGTC to Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting
07:30am, Wednesday, 28'th Apr 2021
AAV-mediated gene therapy rescues hearing and cochlear damage in two preclinical models of congenital hearing loss caused by GJB2 deficiency AAV-mediated gene therapy rescues hearing and cochlear dama
Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
07:30am, Monday, 19'th Apr 2021
SAN DIEGO, April 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the clo
Otonomy Announces Pricing of $30.1 Million Public Offering
10:02pm, Wednesday, 07'th Apr 2021
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pri
Otonomy Announces Proposed Public Offering
04:06pm, Wednesday, 07'th Apr 2021
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it
Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting
07:30am, Monday, 05'th Apr 2021
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pr
Are Options Traders Betting on a Big Move in Otonomy (OTIC) Stock?
12:08pm, Friday, 26'th Feb 2021
Investors need to pay close attention to Otonomy (OTIC) stock based on the movements in the options market lately.
Otonomy to Participate in Three Upcoming Investor Conferences
07:30am, Thursday, 25'th Feb 2021
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that ma
Otonomy stock loses half its value after disappointing trial results of vertigo treatment
08:37am, Monday, 22'nd Feb 2021
Shares of Otonomy Inc. plunged 50.1% to pace all premarket decliners, after the biopharmaceutical company said Phase 3 trial of its Ménière's disease (vertigo) treatment failed to meet its primary e
Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's Disease
07:00am, Monday, 22'nd Feb 2021
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that th
